An open label study in children to assess the clinical and serological effects along with safety of rituximab for the treatment of systemic lupus erythematosus.

Trial Profile

An open label study in children to assess the clinical and serological effects along with safety of rituximab for the treatment of systemic lupus erythematosus.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2015

At a glance

  • Drugs Rituximab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 06 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top